Acute Biliary Pancreatitis Diagnosed
Pancreatitis + gallstones/biliary sludge on imaging
All Pathways
GastroenterologyManagement
Acute Biliary Pancreatitis - GI Management (ACG 2024)
Acute Biliary Pancreatitis - GI Management (ACG 2024): Acute Biliary Pancreatitis Diagnosed → Assess Severity & Cholangitis → Concomitant Cholangitis? →...
Pathway Overview
14 steps
Algorithm Steps
14 total
01Start 02Action Assess Severity & Cholangitis
Key decision points for ERCP
- BISAP, APACHE II, or Ranson's score
- Signs of cholangitis: fever, RUQ pain, jaundice (Charcot's)
- Worsening LFTs (especially bilirubin)
- CBD dilation on imaging (>6mm or >8mm if post-CCY)
03Decision Concomitant Cholangitis?
Tokyo Guidelines criteria
04Warning ⚠️ Urgent/Emergent ERCP
Within 24 hours (ideally <12h if sepsis)
- Definite cholangitis = ERCP within 24 hours
- Severe cholangitis/sepsis = <12 hours
- Sphincterotomy + stone extraction
- Biliary stent if unable to clear duct
05Decision Pancreatitis Resolving?
Pain improving, tolerating diet, normalizing labs
06Action Same-Admission Cholecystectomy
STRONGLY recommended for mild biliary pancreatitis
- Reduces recurrent pancreatitis by 75%
- Perform before discharge if mild disease
- Laparoscopic preferred
- IOC to confirm CBD clear
- Delay only if severe pancreatitis/local complications
07Outcome Biliary Pancreatitis Resolved
CCY done, biliary tract cleared - no further intervention needed
08Action Severe Pancreatitis - Delayed CCY
Wait for local complications to resolve
- Delay 6+ weeks if necrosis/collections
- Interval cholecystectomy when recovered
- High recurrence risk if CCY not done (~30-50%)
09Outcome Outpatient Follow-up
Schedule cholecystectomy within 2-6 weeks if not done inpatient
10Decision Persistent CBD Obstruction?
Elevated bili, dilated CBD without cholangitis
11Action CBD Stone Probability Assessment
Risk stratification for CBD stone
- High risk: CBD stone on US, cholangitis, bili >4
- Intermediate: CBD dilation, bili 1.8-4, abnormal LFTs
- Low risk: normal labs and no CBD dilation
12Action High Risk → ERCP
Direct to ERCP without further imaging
- ERCP within 24-72 hours
- Sphincterotomy + stone extraction
- No need for MRCP/EUS first
- Path rejoins step 05Shared downstream outcome
13Action Intermediate Risk → MRCP/EUS
Further imaging to confirm CBD stone
- MRCP or EUS preferred (non-invasive)
- Sensitivity ~95% for CBD stones
- ERCP if stone confirmed
- Avoid unnecessary ERCP (PEP risk)
- Path rejoins step 05Shared downstream outcome
14Action Low Risk → Observe
No ERCP, proceed to cholecystectomy
- Labs normalizing
- No CBD dilation
- ERCP NOT indicated for all biliary pancreatitis
- IOC at time of cholecystectomy
- Path rejoins step 05Shared downstream outcome
Guideline Source
ACG Clinical Guideline: Acute Pancreatitis 2024
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- ERCP timing is critical and evolving
- Cholangitis determination requires clinical judgment
- MRCP availability may delay diagnosis
- Same-admission cholecystectomy requires surgical coordination
Applicable Regions
USEUGlobal
EU: Similar to IAP/APA guidelines
US: ACG 2024 is current standard
Version 1Next review: 2027-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Calculator
Glasgow-Blatchford Bleeding Score
Upper GI bleed risk stratification and need for intervention
Open page
Compare
AttendMe.ai vs UpToDate
See how this pathway workflow compares against UpToDate.
Open page
Commercial
Start free
Run the pathway in a live AttendMe account with citations and tracked usage.
Start free
Related Resources
Frequently Asked Questions
What is the Acute Biliary Pancreatitis - GI Management (ACG 2024)?
The Acute Biliary Pancreatitis - GI Management (ACG 2024) is a management clinical algorithm for Gastroenterology. It provides a structured decision tree to guide clinical decision-making, based on ACG Clinical Guideline: Acute Pancreatitis 2024.
What guideline is the Acute Biliary Pancreatitis - GI Management (ACG 2024) based on?
This algorithm is based on ACG Clinical Guideline: Acute Pancreatitis 2024 (DOI: 10.14309/ajg.0000000000002645).
What are the limitations of the Acute Biliary Pancreatitis - GI Management (ACG 2024)?
Known limitations include: ERCP timing is critical and evolving; Cholangitis determination requires clinical judgment; MRCP availability may delay diagnosis; Same-admission cholecystectomy requires surgical coordination. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Acute Biliary Pancreatitis - GI Management (ACG 2024) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free